ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and low to intermediate anatomical complexity. However, it remains a technically challenging procedure, particularly regarding stent expansion and apposition, lesion coverage, and the various bifurcation strategies.

Cobertura Científica SOLACI ACC 2026

The aim of the OPTIMAL study was to determine whether an IVUS-guided PCI strategy could reduce the risk of ischemic events or death compared with a qualitatively angiography-guided PCI strategy in patients with unprotected LMCA disease.

This was an international, multicenter, randomized, open-label superiority trial conducted across 28 European centers in Italy, Spain, and the United Kingdom. A total of 806 patients were randomized, with 401 assigned to IVUS-guided PCI and 405 to angiography-guided PCI. The primary endpoint was a patient-oriented composite outcome of all-cause death, any stroke, any myocardial infarction, or any revascularization during extended follow-up.

The mean age was 71.1 years, and 78% were male. Clinical presentation included non-ST-elevation myocardial infarction in approximately 39%, unstable angina in about 10%, and chronic coronary syndrome in roughly half of the patients. The anatomical SYNTAX score was 30.10 ± 13.0 in the IVUS arm and 29.29 ± 12.1 in the angiography arm. The stents used were Synergi or Synergi Megatron.

Read also: ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation.

From a procedural standpoint, total procedure time was longer in the IVUS arm (88.6 ± 50.2 min vs 63.9 ± 37.6 min), with similar rates of periprocedural complications (7.4% vs 7.2%).

Regarding outcomes, at a mean follow-up of 2.9 years, the patient-oriented endpoint occurred in 33.7% of patients in the IVUS group and 30.9% in the angiography-guided group (HR 1.11; 95% CI 0.87–1.42; p=0.40). No differences were observed in secondary composite endpoints. The device-oriented endpoint (cardiovascular death, target vessel myocardial infarction, or clinically indicated TLR) occurred in 22.4% of the IVUS arm and 20.5% of the angiography arm (HR 1.10; 95% CI 0.82–1.49).

Conclusions:
In this randomized study of patients with unprotected left main coronary artery disease, IVUS-guided PCI was not associated with a lower risk of the composite endpoint of stroke, myocardial infarction, revascularization, or death compared with angiography-guided PCI at a mean follow-up of 2.9 years. These findings suggest that an angiography-only strategy may be appropriate when procedures are performed by IVUS-experienced operators in high-volume centers.

Presented by Luca Testa in the Late-Breaking Clinical Trials sessions at ACC.26, March 28–30, New Orleans, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...